UroGen Pharma Announces Results From ENVISION And ATLAS Clinical Studies Exploring Investigational Therapy UGN-102 For Intravesical Solution For Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

• Presents 18-month duration of response (DOR) data from the ENVISION study
• Analyzes the impact of tumor burden or focality in recurrent LG-IR-NMIBC, a substudy from ENVISION
• Reports ENVISION and ATLAS complete response and DOR data

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the ENVISION and ATLAS clinical studies exploring investigational therapy UGN-102 (mitomycin) for intravesical solution for the treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The data are featured at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

UGN-102 data featured at ASCO:

• Duration of Response (DOR) Following Treatment with UGN-102 in Patients with Recurrent, Low-Grade, Intermediate-Risk, Non-Muscle Invasive, Bladder Cancer: 18-Month DOR Data from the Phase 3 ENVISION Trial: Abstract #4598, Poster #398
• Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment with UGN-102: A Substudy of the Phase 3 ENVISION Trial: Abstract #4597, Poster #397
• Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer with UGN-102: Results of the Phase 3 ATLAS and ENVISION Studies. Published Abstract 501822